Fast Five Quiz: Alzheimer Disease Management

Jasvinder P. Chawla, MD, MBA

Disclosures

May 23, 2019

Combination therapy with memantine and ChEIs has been found to delay institutionalization in patients with moderate to severe Alzheimer disease. In addition to memantine and ChEIs, rivastigmine (13.3 mg/24 hours) showed improved function and cognition compared with traditional lower dosing (4.6 mg/24 hours).

Creative art classes, antipsychotic medications, increased video game time, < 6 hours of sleep nightly, and treatment with gabapentin 300 mg orally three times daily do not delay institutionalization of patients with moderate to severe Alzheimer disease.

For more on memantine and ChEIs for patients with Alzheimer disease, read here.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....